Aptamer Group: York firm announces leadership shakeup as co-founder steps down from board of directors

Yorkshire-based biotech firm Aptamer Group has announced a shakeup of its senior leadership team, with company co-founder, Dr David Bunka, stepping down as a director.

Aptamer said the senior changes would bring specialist expertise in a medical technology known as oligonucleotide therapeutics, which uses precisely designed DNA or RNA strands to target the underlying drivers of diseases.

Dr Paloma Giangrande, a member of the company’s Scientific Advisory Board, joins the board as a non-executive director, while her husband, Dr James McNamara, is appointed head of oligonucleotide therapeutic development.

Dr Bunka will remain with the company as head of research and development, but steps down from the role of director which he has held since co-founding the firm in 2008 with Dr Arron Tolley.

Dr Arron Tolley, CEO of Aptamer Group.placeholder image
Dr Arron Tolley, CEO of Aptamer Group.

Speaking on the appointments, Dr Adam Hargreaves, chair of the board, said: “On behalf of the board, I am delighted to welcome Paloma as a non-executive director.

“She has taken RNA medicines from discovery into the clinic and has worked with our team through the Scientific Advisory Board since December 2024. Her experience will strengthen the board’s oversight of our therapeutic programmes, including the in vivo study in Optimer-targeted radiotherapy led by Dr Louis Allott, director of Radioligand Development, and the oligonucleotide delivery studies James will lead.

“I also thank David for his contribution as a Director since the Company’s foundation and look forward to his continued contribution as head of research and development.”

Dr Giangrande is an expert in nucleic acid therapeutics and delivery, having previously conducted pioneering work at the University of Iowa.

She has also held senior leadership roles at Moderna and Wave Life Sciences, where she took an RNA editing programme into first-in-human studies, and at Eleven Therapeutics, where she was chief technology officer.

Most recently, she was senior vice president of discovery and translational biology at Orbital

Therapeutics, where she oversaw programmes acquired by Bristol Myers Squibb in December 2025 for $1.5bn.

Speaking on her appointment on Aptamer’s board, Dr Giangrande said: “Having worked with the team through the Scientific Advisory Board and seen first-hand what the Optimer platform can do, I am pleased to be joining the board.”

Dr McNamara was associate professor of internal medicine at the University of Iowa and founder and chief executive officer of Nuclease Probe Technologies, Inc., which developed nucleic acid-based diagnostics for bacterial pathogens.

Dr Arron Tolley, chief executive officer of Aptamer Group, added: “I have worked with Paloma for almost two years through the Scientific Advisory Board, and I am delighted to welcome her to the board and James as head of oligonucleotide therapeutic development.

“Both Paloma and James helped pioneer aptamer-mediated siRNA delivery, and their expertise adds translational depth to our existing team as our programmes move into in vivo evaluation.”

Related topics:
News you can trust since 1754
Follow us
© 2026 Iconic Media Group Ltd. All rights reserved.Cookie SettingsTerms and ConditionsPrivacy notice